Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market, 2012-2023
Global Dipeptidyl Peptidase IV Inhibitors Market
Dipeptidyl Peptidase IV (DPP-IV) inhibitors also known as gliptins are oral anti-diabetic drugs, commonly used in the treatment of Type-2 diabetes. Dipeptidyl Peptidase inhibitors act by inhibiting the degradation of incretins like GLP-1 by inhibition of the enzyme dipeptidyl peptidase IV. The effect of incretin is prolonged, improving the glycemic control by various mechanisms, initially by stimulating the insulin synthesis and secretion in a glucose-dependent manner and by reduction of glucagon secretion. Dipeptidyl Peptidase IV inhibitors are commonly prescribed for the patients with type 2 diabetes especially who are not responded well to sulfonyl ureas and metformin. Dipeptidyl Peptidase IV inhibitors decrease blood glucose levels and help in weight loss. The common adverse effects associated with DPP IV inhibitors is Pancreatitis.
The global dipeptidyl peptidase IV (DPP-IV) inhibitors market is expected to grow at a significant CAGR due to increase in the prevalence and incidence of diabetes. The excellent safety profile of dipeptidyl peptidase IV inhibitors, growing investments in the R&D activities, convenience benefit of being an oral medication, and acceptance of dipeptidyl peptidase IV inhibitors in oral antidiabetic drug class might fuel the dipeptidyl peptidase IV inhibitors market over the forecast period. Furthermore, favourable reimbursement policies for diabetes treatment, and low cost for dipeptidyl peptidase IV inhibitors expected to boost the dipeptidyl peptidase-IV inhibitors market over the forecast period. However, stringent regulatory policies, adverse effects associated with dipeptidyl peptidase IV inhibitors might hamper the dipeptidyl peptidase IV inhibitors market growth over the forecast period.
Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market segmented on the basis of drug type, and distribution channel
Based on drug type, dipeptidyl peptidase IV Inhibitors market is segmented into the following:
Geographically, the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market has been segmented into following regions Viz. North America, Asia-Pacific, Latin America, Europe, and Middle East and Africa. North America region is expected to dominate the Dipeptidyl peptidase IV (DPP IV) inhibitors market owing to rise in a number growing diabetic population (according to American Diabetes Association, the prevalence in 2015, 30.3 million or 9.4% of the population, had diabetes in U.S.). Increase in the R&D activities, the launch of new products, and various products which are in the pipeline are some key factors improving the Dipeptidyl peptidase IV inhibitors market share in North America. Europe holds a dominant share owing to change in lifestyle, which causes diabetes, increase in the prevalence of diabetes (according to Diabetes UK 2016, about 3.6 Mn people are suffering from diabetes in the U.K. region), and an increase in the R&D might boost the dipeptidyl peptidase IV (DPP-IV) inhibitors market over the forecast period. Emerging nations in the Asia- Pacific is expected to offer lucrative opportunities in the near future due to increase in population, and an increase in diabetes incidence. According to the International Diabetes Federation, China had around 96.2 million diabetic patients and India had 66.8 million patients with diabetes. In 2015, approximately 45% of the global diabetic patients are from India and China, which increases the growth of global dipeptidyl peptidase IV (DPP-IV) inhibitors market in Asia-Pacific.
Some of the players in dipeptidyl peptidase IV Inhibitors market are AstraZeneca Plc. (UK), Boehringer Ingelheim GmbH (Germany), Eli Lilly and Company (U.S.), Merck & Co, Inc. (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sanofi (France), Bristol-Myers Squibb (U.S.), GlaxoSmithKline Plc. (U.K.), Pfizer, Inc. (U.S.), Otsuka Holdings Co. Ltd. (Japan), Ornamed Pharmaceutical, Inc. (Israel), Dr. Reddy’s Laboratories, Ltd. (India), and Novo Nordisk A/S (Denmark) to name a few.
In July 2016, Sanofi-Synthelabo India Private Limited announced the launch of Zemiglo (gemigliptin) is a once daily, oral tablet
In October 2015, Lupin and Boehringer Ingelheim announced that a joint strategic alliance for co-marketing Linagliptin, a novel dipeptidyl
Dipeptidyl Peptidase IV (DPP-IV) inhibitors also known as gliptins are oral anti-diabetic drugs, commonly used in the treatment of Type-2 diabetes. Dipeptidyl Peptidase inhibitors act by inhibiting the degradation of incretins like GLP-1 by inhibition of the enzyme dipeptidyl peptidase IV. The effect of incretin is prolonged, improving the glycemic control by various mechanisms, initially by stimulating the insulin synthesis and secretion in a glucose-dependent manner and by reduction of glucagon secretion. Dipeptidyl Peptidase IV inhibitors are commonly prescribed for the patients with type 2 diabetes especially who are not responded well to sulfonyl ureas and metformin. Dipeptidyl Peptidase IV inhibitors decrease blood glucose levels and help in weight loss. The common adverse effects associated with DPP IV inhibitors is Pancreatitis.
The global dipeptidyl peptidase IV (DPP-IV) inhibitors market is expected to grow at a significant CAGR due to increase in the prevalence and incidence of diabetes. The excellent safety profile of dipeptidyl peptidase IV inhibitors, growing investments in the R&D activities, convenience benefit of being an oral medication, and acceptance of dipeptidyl peptidase IV inhibitors in oral antidiabetic drug class might fuel the dipeptidyl peptidase IV inhibitors market over the forecast period. Furthermore, favourable reimbursement policies for diabetes treatment, and low cost for dipeptidyl peptidase IV inhibitors expected to boost the dipeptidyl peptidase-IV inhibitors market over the forecast period. However, stringent regulatory policies, adverse effects associated with dipeptidyl peptidase IV inhibitors might hamper the dipeptidyl peptidase IV inhibitors market growth over the forecast period.
Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market segmented on the basis of drug type, and distribution channel
Based on drug type, dipeptidyl peptidase IV Inhibitors market is segmented into the following:
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Geographically, the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market has been segmented into following regions Viz. North America, Asia-Pacific, Latin America, Europe, and Middle East and Africa. North America region is expected to dominate the Dipeptidyl peptidase IV (DPP IV) inhibitors market owing to rise in a number growing diabetic population (according to American Diabetes Association, the prevalence in 2015, 30.3 million or 9.4% of the population, had diabetes in U.S.). Increase in the R&D activities, the launch of new products, and various products which are in the pipeline are some key factors improving the Dipeptidyl peptidase IV inhibitors market share in North America. Europe holds a dominant share owing to change in lifestyle, which causes diabetes, increase in the prevalence of diabetes (according to Diabetes UK 2016, about 3.6 Mn people are suffering from diabetes in the U.K. region), and an increase in the R&D might boost the dipeptidyl peptidase IV (DPP-IV) inhibitors market over the forecast period. Emerging nations in the Asia- Pacific is expected to offer lucrative opportunities in the near future due to increase in population, and an increase in diabetes incidence. According to the International Diabetes Federation, China had around 96.2 million diabetic patients and India had 66.8 million patients with diabetes. In 2015, approximately 45% of the global diabetic patients are from India and China, which increases the growth of global dipeptidyl peptidase IV (DPP-IV) inhibitors market in Asia-Pacific.
Some of the players in dipeptidyl peptidase IV Inhibitors market are AstraZeneca Plc. (UK), Boehringer Ingelheim GmbH (Germany), Eli Lilly and Company (U.S.), Merck & Co, Inc. (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sanofi (France), Bristol-Myers Squibb (U.S.), GlaxoSmithKline Plc. (U.K.), Pfizer, Inc. (U.S.), Otsuka Holdings Co. Ltd. (Japan), Ornamed Pharmaceutical, Inc. (Israel), Dr. Reddy’s Laboratories, Ltd. (India), and Novo Nordisk A/S (Denmark) to name a few.
In July 2016, Sanofi-Synthelabo India Private Limited announced the launch of Zemiglo (gemigliptin) is a once daily, oral tablet
In October 2015, Lupin and Boehringer Ingelheim announced that a joint strategic alliance for co-marketing Linagliptin, a novel dipeptidyl
1. EXECUTIVE SUMMARY
2. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET INTRODUCTION
2.1. Global Dipeptidyl Peptidase IV Inhibitors Market – Taxonomy
2.2. Global Dipeptidyl Peptidase IV Inhibitors Market –Definitions
2.2.1. Drugs
2.2.2. Distribution Channel
3. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Factors Impact Analysis
3.6. Global Dipeptidyl Peptidase IV Inhibitors Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.7. Global Dipeptidyl Peptidase IV Inhibitors Market – Product Pipeline Analysis
4. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET, BY DRUGS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Sitagliptin
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Vildagliptin
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Saxagliptin
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Linagliptin
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. On-line Pharmacies
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. North America
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel, and Region, 2017 – 2023
8. NORTH AMERICA DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1.1. Sitagliptin
8.1.1.2. Vildagliptin
8.1.1.3. Saxagliptin
8.1.1.4. Linagliptin
8.1.1.5. Others
8.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.1.2.1. Hospital Pharmacies
8.1.2.2. Retail Pharmacies
8.1.2.3. On-line Pharmacies
8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.1.3.1. U.S.
8.1.3.2. Canada
8.1.4. North America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
8.1.5. North America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
9. EUROPE DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Sitagliptin
9.1.1.2. Vildagliptin
9.1.1.3. Saxagliptin
9.1.1.4. Linagliptin
9.1.1.5. Others
9.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Hospital Pharmacies
9.1.2.2. Retail Pharmacies
9.1.2.3. On-line Pharmacies
9.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Germany
9.1.3.2. UK
9.1.3.3. France
9.1.3.4. Spain
9.1.3.5. Italy
9.1.3.6. Russia
9.1.3.7. Poland
9.1.3.8. Rest of Europe
9.1.4. Europe Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
9.1.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
10. ASIA-PACIFIC DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Sitagliptin
10.1.1.2. Vildagliptin
10.1.1.3. Saxagliptin
10.1.1.4. Linagliptin
10.1.1.5. Others
10.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Hospital Pharmacies
10.1.2.2. Retail Pharmacies
10.1.2.3. On-line Pharmacies
10.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
10.1.3.1. Japan
10.1.3.2. China
10.1.3.3. India
10.1.3.4. ASEAN
10.1.3.5. Australia & New Zealand
10.1.3.6. Rest of Asia-Pacific
10.1.4. Asia-Pacific Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
10.1.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
11. LATIN AMERICA DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Sitagliptin
11.1.1.2. Vildagliptin
11.1.1.3. Saxagliptin
11.1.1.4. Linagliptin
11.1.1.5. Others
11.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Hospital Pharmacies
11.1.2.2. Retail Pharmacies
11.1.2.3. On-line Pharmacies
11.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Brazil
11.1.3.2. Mexico
11.1.3.3. Argentina
11.1.3.4. Venezuela
11.1.3.5. Rest of Latin America
11.1.4. Latin America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
11.1.5. Latin America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
12. MIDDLE EAST AND AFRICA DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Sitagliptin
12.1.1.2. Vildagliptin
12.1.1.3. Saxagliptin
12.1.1.4. Linagliptin
12.1.1.5. Others
12.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Hospital Pharmacies
12.1.2.2. Retail Pharmacies
12.1.2.3. On-line Pharmacies
12.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3.1. Gulf Cooperation Council (GCC) Countries
12.1.3.2. Israel
12.1.3.3. South Africa
12.1.3.4. Rest of MEA
12.1.4. MEA Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
12.1.5. MEA Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
13. COMPETITION LANDSCAPE
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. AstraZeneca Plc. (UK)
13.2.2. Boehringer Ingelheim GmbH (Germany)
13.2.3. Eli Lilly and Company (U.S.)
13.2.4. Merck & Co, Inc. (U.S.)
13.2.5. Mitsubishi Tanabe Pharma Corporation (Japan)
13.2.6. Novartis AG (Switzerland)
13.2.7. Takeda Pharmaceutical Company Limited (Japan)
13.2.8. Sanofi (France)
13.2.9. Bristol-Myers Squibb (U.S.)
13.2.10. GlaxoSmithKline Plc. (U.K.)
13.2.11. Pfizer, Inc. (U.S.)
13.2.12. Otsuka Holdings Co. Ltd. (Japan)
13.2.13. Ornamed Pharmaceutical, Inc. (Israel)
13.2.14. Dr. Reddy’s Laboratories, Ltd. (India)
13.2.15. Novo Nordisk A/S (Denmark)
14. RESEARCH METHODOLOGY
15. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET INTRODUCTION
2.1. Global Dipeptidyl Peptidase IV Inhibitors Market – Taxonomy
2.2. Global Dipeptidyl Peptidase IV Inhibitors Market –Definitions
2.2.1. Drugs
2.2.2. Distribution Channel
3. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Factors Impact Analysis
3.6. Global Dipeptidyl Peptidase IV Inhibitors Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.7. Global Dipeptidyl Peptidase IV Inhibitors Market – Product Pipeline Analysis
4. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET, BY DRUGS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Sitagliptin
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Vildagliptin
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Saxagliptin
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Linagliptin
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. On-line Pharmacies
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. North America
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel, and Region, 2017 – 2023
8. NORTH AMERICA DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1.1. Sitagliptin
8.1.1.2. Vildagliptin
8.1.1.3. Saxagliptin
8.1.1.4. Linagliptin
8.1.1.5. Others
8.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.1.2.1. Hospital Pharmacies
8.1.2.2. Retail Pharmacies
8.1.2.3. On-line Pharmacies
8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.1.3.1. U.S.
8.1.3.2. Canada
8.1.4. North America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
8.1.5. North America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
9. EUROPE DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Sitagliptin
9.1.1.2. Vildagliptin
9.1.1.3. Saxagliptin
9.1.1.4. Linagliptin
9.1.1.5. Others
9.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Hospital Pharmacies
9.1.2.2. Retail Pharmacies
9.1.2.3. On-line Pharmacies
9.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Germany
9.1.3.2. UK
9.1.3.3. France
9.1.3.4. Spain
9.1.3.5. Italy
9.1.3.6. Russia
9.1.3.7. Poland
9.1.3.8. Rest of Europe
9.1.4. Europe Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
9.1.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
10. ASIA-PACIFIC DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Sitagliptin
10.1.1.2. Vildagliptin
10.1.1.3. Saxagliptin
10.1.1.4. Linagliptin
10.1.1.5. Others
10.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Hospital Pharmacies
10.1.2.2. Retail Pharmacies
10.1.2.3. On-line Pharmacies
10.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
10.1.3.1. Japan
10.1.3.2. China
10.1.3.3. India
10.1.3.4. ASEAN
10.1.3.5. Australia & New Zealand
10.1.3.6. Rest of Asia-Pacific
10.1.4. Asia-Pacific Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
10.1.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
11. LATIN AMERICA DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Sitagliptin
11.1.1.2. Vildagliptin
11.1.1.3. Saxagliptin
11.1.1.4. Linagliptin
11.1.1.5. Others
11.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Hospital Pharmacies
11.1.2.2. Retail Pharmacies
11.1.2.3. On-line Pharmacies
11.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Brazil
11.1.3.2. Mexico
11.1.3.3. Argentina
11.1.3.4. Venezuela
11.1.3.5. Rest of Latin America
11.1.4. Latin America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
11.1.5. Latin America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
12. MIDDLE EAST AND AFRICA DIPEPTIDYL PEPTIDASE IV INHIBITORS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Sitagliptin
12.1.1.2. Vildagliptin
12.1.1.3. Saxagliptin
12.1.1.4. Linagliptin
12.1.1.5. Others
12.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Hospital Pharmacies
12.1.2.2. Retail Pharmacies
12.1.2.3. On-line Pharmacies
12.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3.1. Gulf Cooperation Council (GCC) Countries
12.1.3.2. Israel
12.1.3.3. South Africa
12.1.3.4. Rest of MEA
12.1.4. MEA Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
12.1.5. MEA Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
13. COMPETITION LANDSCAPE
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. AstraZeneca Plc. (UK)
13.2.2. Boehringer Ingelheim GmbH (Germany)
13.2.3. Eli Lilly and Company (U.S.)
13.2.4. Merck & Co, Inc. (U.S.)
13.2.5. Mitsubishi Tanabe Pharma Corporation (Japan)
13.2.6. Novartis AG (Switzerland)
13.2.7. Takeda Pharmaceutical Company Limited (Japan)
13.2.8. Sanofi (France)
13.2.9. Bristol-Myers Squibb (U.S.)
13.2.10. GlaxoSmithKline Plc. (U.K.)
13.2.11. Pfizer, Inc. (U.S.)
13.2.12. Otsuka Holdings Co. Ltd. (Japan)
13.2.13. Ornamed Pharmaceutical, Inc. (Israel)
13.2.14. Dr. Reddy’s Laboratories, Ltd. (India)
13.2.15. Novo Nordisk A/S (Denmark)
14. RESEARCH METHODOLOGY
15. KEY ASSUMPTIONS AND ACRONYMS